Celcuity Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CELC$67.05-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(52,841) | $(36,997) |
| Adjustments to reconcile net loss to net cash and cash equivalents used in operations: | ||
| Depreciation | 47 | 37 |
| Stock-based compensation | 5,325 | 2,444 |
| Amortization of debt issuance costs and discount | 1,252 | 551 |
| Payment-in-kind interest | 325 | 249 |
| Non-cash interest income | (883) | (946) |
| Non-cash operating lease expense | (3) | (1) |
| Changes in operating assets and liabilities: | ||
| Prepaid clinical trial costs | 3,522 | (2,118) |
| Other current assets | (976) | (318) |
| Accounts payable | 4,080 | 613 |
| Accrued clinical trial costs | (8,055) | 1,504 |
| Other accrued expenses | (6,858) | (871) |
| Net cash used in operating activities | (55,065) | (35,853) |
| Cash flows from investing activities: | ||
| Proceeds from maturities of investments | 50,000 | 66,808 |
| Purchases of investments | (15,196) | (42,486) |
| Purchases of property and equipment | (249) | (60) |
| Purchases of capitalized software | (36) | — |
| Net cash provided by investing activities | 34,519 | 24,262 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options | 206 | — |
| Proceeds from exercise of common stock warrants | 31 | 5,600 |
| Payments for secondary registration statement costs | (203) | (46) |
| Net cash provided by financing activities | 34 | 5,554 |
| Net change in cash and cash equivalents | (20,512) | (6,037) |
| Cash and cash equivalents: | ||
| Beginning of period | 165,703 | 22,515 |
| End of period | $145,191 | $16,478 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $5,889 | $2,383 |
| Cash paid for operating leases | $56 | $54 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Capitalized software included in accounts payable | $85 | $— |
| Exercise of stock options pending receipt of cash proceeds | $249 | $2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.